Video

Updated Efficacy and Safety of Larotrectinib in Patients with Advanced Tropomyosin Receptor Kinase (TRK) Fusion Positive Thyroid Carcinoma

Dr Cabanillas reviews updated data that was recently presented at the American Thyroid Association conference on the use of larotrectinib in patients with advanced TRK fusion positive thyroid cancer.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Background

    • Larotrectinib is a highly selective TRK inhibitor which has shown a 71% overall response rate (ORR) in 28 investigator-evaluable patients with TRK fusion-positive thyroid carcinoma (TC) as of July 2020.
    • We report data on an expanded dataset of patients with TRK fusion-positive TC treated with larotrectinib.

    Methods

    • Patients from 3 larotrectinib clinical trials (NCT02576431, NCT02122913, NCT02637687) were included.
    • Larotrectinib was administered at 100mg twice daily.
    • Responses were assessed per independent review committee using RECIST version 1.1.

    Results

    • As of July 2021, 30 patients with TRK fusion-positive TC (medican age, 61.5 years [range, 6-80 years]) were enrolled, including 29 individuals with an additional year of follow-up.
    • Seven patients (23%) had recieved 2 prior systemic therapies; 26 patients (87%) had recieved prior radioiodine.
    • ORR was 63% (95% CI, 44%-80%). In all, 3 patients (10%) had complete responses, 16 patients (54%) had partial responses, 5 patients (17%) had stable disease (all with target lesion shrinkage), and 4 patients (13%) had progressive disease (3 with anaplastic TC [ATC]); responses in 2 patients (17%) were not determined.
    • For patients classified as having differentiated TC (DTC; n = 23), ORR was 78% (95% CI, 56%-93%); for patients classified as having ATC (n = 7), ORR was 14% (95% CI, 0%-58%).
    • In all responders, median time to response was 1.9 months, median duration of response (DOR) was 43.3 months (95% CI, 21.6 months to not estimable [NE]), and median follow-up was 28.8 months.
    • Median progression-free survival (PFS) was 48.7 months (95% CI, 27.8 months to NE); median follow-up was 34.1 months.
    • For DTC, the median DOR, PFS, and OS were 43.3 months, 48.7 months, and not reached, respectively.
    • For ATC, the median DOR, PFS, and OS were 3.7, 2.2, and 8.8 months, respectively.
    • Treatment-related adverse events (TRAEs) were mostly grade 1 or 2. Grade 3 anemia and decreased lymphocyte count were reported in 2 patinets (7%); none of the patients discontinued treatment due to TRAEs.

    Conclusions

    • Larotrectinib demonstrated a high ORR, rapid and durable disease control, and an overall favorable safety profile in patients with TRK fusion-positive DTC.
    • These data support testing for TRK fusions in patients with advanced TC requiring systemic therapy.

    Cabanillas ME, Lin JJ, Brose MS et al. Updated Efficacy and Safety of Larotrectinib in Patients with Advanced Tropomyosin Receptor Kinase (TRK) Fusion Positive Thyroid Carcinoma. Abstract presented at: 2022 American Tyroid Association Annual Meeting, October 19-23, 2022; Abstract# Poster 108. https://www.liebertpub.com/doi/epdf/10.1089/thy.2022.29137.abstracts

    Related Videos
    Safety and Efficacy of BAY 2927088 in Patients with HER2-Mutant NSCLC: Expansion Cohort from the Phase I/II SOHO-01 Study
    Safety and Efficacy of BAY 2927088 in Patients with HER2-Mutant NSCLC: Expansion Cohort from the Phase I/II SOHO-01 Study
    Tagraxofusp Achieves Anti-tumor Activity With Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial
    Tagraxofusp Achieves Anti-Tumor Activity with Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial
    First results of nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite instability high/ mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW
    First results of nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite instability high/ mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW
    CDAC CLL
    Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase 1 CaDAnCe-101 study
    Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma
    Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma
    Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
    Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
    Phase 3 AMPLIFY Trial
    Fixed-Duration Acalabrutinib plus Venetoclax With or Without Obinutuzumab versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial
    RLY-2608
    Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor, in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial
    BOVen
    Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow Up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)
    RMC-6236
    Updated safety and efficacy from a Phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)
    Related Content